Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Acq. announced Director departure
|
Aprea Therapeutics, Inc. (APRE)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/24/2023 |
4
| Pamukcu Rifat (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Converted 49,280 shares
@ $0 Granted 500 shares
@ $0 Converted 271,870 shares
@ $0 Converted 4,928 options to buy
@ $0 Converted 27,187 options to buy
@ $0 Granted 2,000 options to buy
@ $3.65, valued at
$7.3k
|
|
08/24/2023 |
4
| Grissinger Michael (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 500 shares
@ $0 Granted 2,000 options to buy
@ $3.65, valued at
$7.3k
|
|
08/24/2023 |
4
| HENNEMAN JOHN B III (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 500 shares
@ $0 Granted 2,000 options to buy
@ $3.65, valued at
$7.3k
|
|
08/24/2023 |
4
| Peters Richard (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 500 shares
@ $0 Granted 2,000 options to buy
@ $3.65, valued at
$7.3k
|
|
08/24/2023 |
4
| Duey Marc (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Converted 4,009,690 shares
@ $0 Granted 500 shares
@ $0 Converted 11,610 shares
@ $0 Converted 400,969 options to buy
@ $0 Converted 1,161 options to buy
@ $0 Granted 2,000 options to buy
@ $3.65, valued at
$7.3k
|
|
08/24/2023 |
4
| Seizinger Bernd R. (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 500 shares
@ $0 Granted 2,000 options to buy
@ $3.65, valued at
$7.3k
|
|
08/24/2023 |
4
| BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 12,500 options to buy
@ $3.65, valued at
$45.6k
|
|
06/08/2023 |
4
| Seizinger Bernd R. (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Bought 4,068 shares
@ $3.6294, valued at
$14.8k
Bought 6,029 shares
@ $3.6809, valued at
$22.2k
|
|
05/08/2023 |
4
| Gruia Gabriela (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 12,500 options to buy
@ $3.8999, valued at
$48.7k
|
|
03/13/2023 |
4
| Gilad Oren (President, CEO) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Converted 6,045,100 shares
@ $0 Granted 4,000 shares
@ $0 Converted 604,510 options to buy
@ $0 Granted 16,000 options to buy
@ $5.08, valued at
$81.3k
|
|
02/27/2023 |
4
| Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 1,000 shares
@ $5.25, valued at
$5.3k
|
|
01/30/2023 |
4
| Hamill John P. (SrVP/CFO/Prin. Fin&Acctg. Off) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 269,879 shares
@ $0 Granted 539,758 options to buy
@ $0.496, valued at
$267.7k
|
|
08/01/2022 |
4
| Seizinger Bernd R. (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 5,995 shares
@ $0 Granted 29,575 options to buy
@ $1.09, valued at
$32.2k
|
|
08/01/2022 |
4
| SCHADE CHRISTIAN S (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 32,400 shares
@ $0 Granted 47,600 options to buy
@ $1.09, valued at
$51.9k
|
|
08/01/2022 |
4
| Peters Richard (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 5,995 shares
@ $0 Granted 29,575 options to buy
@ $1.09, valued at
$32.2k
|
|
08/01/2022 |
4
| Pamukcu Rifat (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 5,995 shares
@ $0 Granted 29,575 options to buy
@ $1.09, valued at
$32.2k
|
|
08/01/2022 |
4
| Korbel Gregory Alan (SVP, COO) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 24,300 shares
@ $0 Granted 35,700 options to buy
@ $1.09, valued at
$38.9k
|
|
08/01/2022 |
4
| HENNEMAN JOHN B III (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 5,995 shares
@ $0 Granted 29,575 options to buy
@ $1.09, valued at
$32.2k
|
|
08/01/2022 |
4
| Grissinger Michael (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 5,995 shares
@ $0 Granted 29,575 options to buy
@ $1.09, valued at
$32.2k
|
|
08/01/2022 |
4
| Gilad Oren (President, CEO) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 101,300 shares
@ $0 Granted 148,700 options to buy
@ $1.09, valued at
$162.1k
|
|
08/01/2022 |
4
| Duey Marc (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 5,995 shares
@ $0 Granted 29,575 options to buy
@ $1.09, valued at
$32.2k
|
|
08/01/2022 |
4
| Coiante Scott M (SVP, CFO) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 60,800 shares
@ $0 Granted 89,200 options to buy
@ $1.09, valued at
$97.2k
|
|
06/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/07/2022 |
4
| Korbel Gregory Alan (SVP, COO) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 8,390 shares
@ $0.805, valued at
$6.8k
|
|
06/07/2022 |
4
| Attar Eyal C. (SVP, Chief Medical Officer) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 32,667 shares
@ $0.805, valued at
$26.3k
|
|
05/19/2022 |
4
| Seizinger Bernd R. (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Bought 50,000 shares
@ $0.71, valued at
$35.5k
|
|
05/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/14/2022 |
4
| SCHADE CHRISTIAN S (Chairman & CEO) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 100,100 shares
@ $0 Granted 427,700 options to buy
@ $1.82, valued at
$778.4k
|
|
03/14/2022 |
4
| Korbel Gregory Alan (SVP, Chief Business Officer) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 16,000 shares
@ $0 Paid exercise price by delivering 1,989 shares
@ $1.82, valued at
$3.6k
Granted 72,600 options to buy
@ $1.82, valued at
$132.1k
|
|
03/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/14/2022 |
4
| Attar Eyal C. (SVP, Chief Medical Officer) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 42,900 shares
@ $0 Granted 185,900 options to buy
@ $1.82, valued at
$338.3k
|
|
03/14/2022 |
4
| Abrahmsen Lars B. (SVP, Chief Scientific Officer) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns:
| Granted 24,700 shares
@ $0 Granted 100,000 options to buy
@ $1.82, valued at
$182k
|
|
03/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|